Monash Institute of Pharmaceutical Sciences
Professor Charman's group is focused on characterising properties associated with absorption, distribution, metabolism and excretion (ADME) and pharmacokinetics (PK) for new drug candidates. Identifying PK liabilities and integrating this information into drug discovery programs is essential to guide structural modifications, establish pharmacokinetic/pharmacodynamic (PK/PD) relationships and identify strategies to mitigate risks during drug development. The goal is to play significant role in translating chemical and biological discoveries into viable drug candidates that are well-positioned for further development. They have established a successful model for conducting collaborative, multidisciplinary translational research within an academic environment, and have put in place the required systems, processes, platforms, and skill-set to support end-user focused research.